✦ LIBER ✦

492 Adefovir dipivoxil (ADV) demonstrates sustained efficacy in HBeAg- chronic hepatitis B (CHB) patients

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

496 Efficacy and safety of 2 years adefo

✍ M.D. Zeng; Y.M. Mao; G.B. Yao; H. Wang; J.L. Hou; Y.Z. Wang; J.S. Dixon; K.E. Ba 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 116 KB

45 HBsAg seroconversion in adefovir dipi

✍ M. Shiffman; P. Marcellin; L. Jeffers; S. Gordon; M. Peters; M. Rizzetto; P. Bug 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Resistance surveillance of HBEAG— chroni

✍ S. Xiong; H. Yang; C.E. Westland; W.E. Delaney IV; D. Colledge; A. Bartholomeusz 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 162 KB

46 Three year study of adefovir dipivoxi

✍ S. Hadziyannis; N. Tassopoulos; T.T. Chang; J. Heathcote; G. Kitis; M. Rizzetto; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Adefovir dipivoxil 10 mg (ADV) results i

✍ P. Marcellin; S. Hadzyannis; E. Schiff; M. Peters; Y. Benhamou; C. Brosgart; J. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 266 KB

Predicting HBEAG loss by HBV DNA early k

✍ A.U. Neumann; Y. Havlin; T. Ronen; M. Tsiang; M. Wulfsohn; C. Brosgart; J. Fry; 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 148 KB